\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Digital, Industry & Space AI ContinentTo support AI development from the lab to the market, the EU is setting up Testing & Experimentation Facilities (TEFs) for AI.
Through the Digital Europe programme the Commission is co-funding the TEFs to support AI developers to bring trustworthy AI to the market more efficiently, and facilitate its uptake in Europe. TEFs are specialised large-scale reference sites open to all technology providers across Europe to test and experiment at scale state-of-the art AI solutions, including both soft-and hardware products and services, e.g. robots, in real-world environments.
The selected TEFs projects started on January 1st 2023. They focus on the following high-impact sectors:
TEFs can also contribute to the implementation of the Artificial Intelligence Act by supporting regulatory sandboxes in cooperation with competent national authorities for supervised testing and experimentation.
TEFs will be an important part of building the AI ecosystem of excellence and trust to support Europe’s strategic leadership in AI.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
